<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01275157</url>
  </required_header>
  <id_info>
    <org_study_id>13276</org_study_id>
    <secondary_id>I2N-MC-GPBF</secondary_id>
    <nct_id>NCT01275157</nct_id>
  </id_info>
  <brief_title>Disposition of 14C-LY2452473 Following Oral Administration in Healthy Human Subjects</brief_title>
  <official_title>Disposition of [14C]-LY2452473 Following Oral Administration in Healthy Human Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single dose study of radiolabeled [14C]-LY2452473 in healthy male volunteers to&#xD;
      study the absorption, distribution, metabolism, and elimination of LY2452473.&#xD;
&#xD;
      This study is for research purposes only and is not intended to treat any medical condition.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary and fecal excretion of radioactivity over time expressed as a percentage of the total radioactive dose administered</measure>
    <time_frame>baseline up to 22 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetics of LY2452473 and radioactivity maximum observed concentration (Cmax)</measure>
    <time_frame>baseline up to 22 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetics of LY2452473 and radioactivity time of maximum observed concentration (tmax)</measure>
    <time_frame>baseline up to 22 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetics of LY2452473 and radioactivity area under the concentration-time curve from time zero to the last timepoint with a measurable concentration (AUC 0 to tlast)</measure>
    <time_frame>baseline up to 22 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative abundance of LY2452473 and the metabolites of LY2452473 in urine and feces</measure>
    <time_frame>baseline up to 22 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative abundance of LY2452473 and the metabolites of LY2452473 in plasma</measure>
    <time_frame>baseline up to 22 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>LY2452473</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mg, containing 100 micro curies of 14C labeled LY2452473 taken once only</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2452473</intervention_name>
    <description>Administered orally as a liquid suspension</description>
    <arm_group_label>LY2452473</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Experience on average 1 to 2 bowel movements per day&#xD;
&#xD;
          -  Overtly healthy males, as determined by medical history and physical examination&#xD;
&#xD;
          -  Subjects will either be sterile or, if sexually active, agree to use a reliable method&#xD;
             of birth control from check-in until 3 months after the follow-up assessment&#xD;
&#xD;
          -  Are between the body mass index (BMI) of 19 and 29 kg^m2, inclusive&#xD;
&#xD;
          -  Clinical laboratory test results within the normal reference range for the clinical&#xD;
             research unit laboratory or results with acceptable deviations which are judged to be&#xD;
             not clinically significant by the investigator&#xD;
&#xD;
          -  Have venous access sufficient to allow blood sampling&#xD;
&#xD;
          -  Normal blood pressure and pulse rate (sitting) as determined by the investigator&#xD;
&#xD;
          -  Are reliable and willing to make themselves available for the duration of the study&#xD;
             and are willing to follow study procedures&#xD;
&#xD;
          -  Have given written informed consent approved by Lilly and the Institutional Review&#xD;
             Board (IRB) governing the site&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Are currently enrolled in, or discontinued within the last 30 days from, a clinical&#xD;
             trial involving an off-label use of an investigational drug or device other than the&#xD;
             study drug used in this study, or are concurrently enrolled in any other type of&#xD;
             medical research judged not to be scientifically or medically compatible with this&#xD;
             study&#xD;
&#xD;
          -  Have known allergies to LY2452473 or related compounds&#xD;
&#xD;
          -  Within 30 days of the initial dose of study drug, have received treatment with a drug&#xD;
             that has not received regulatory approval for any indication&#xD;
&#xD;
          -  Have a history or presence of cardiovascular, respiratory, hepatic, renal,&#xD;
             gastrointestinal, endocrine, hematological, psychiatric, or neurological disorders&#xD;
             capable of significantly altering the absorption, metabolism, or elimination of drugs;&#xD;
             constituting a risk when taking the study medication or interfering with the&#xD;
             interpretation of data&#xD;
&#xD;
          -  Have any other condition that in the opinion of the investigator would preclude&#xD;
             participation in the study&#xD;
&#xD;
          -  Regularly use known drugs of abuse and/or show positive findings on urinary drug&#xD;
             screening&#xD;
&#xD;
          -  Show evidence of human immunodeficiency virus (HIV) and/or positive human HIV&#xD;
             antibodies&#xD;
&#xD;
          -  Show evidence of hepatitis C and/or positive hepatitis C antibody&#xD;
&#xD;
          -  Show evidence of hepatitis B and/or positive hepatitis B surface antigen&#xD;
&#xD;
          -  Intended use of over-the-counter or herbal medication within 7 days or prescription&#xD;
             medication within 14 days prior to dosing&#xD;
&#xD;
          -  Have donated more than 500 mL of blood within the last month&#xD;
&#xD;
          -  Have an average weekly alcohol intake that exceeds 14 units per week, or are unwilling&#xD;
             to stop alcohol consumption for the duration of the study (1 unit = 12 oz or 360 mL of&#xD;
             beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits)&#xD;
&#xD;
          -  Use of herbal preparations containing St. John's Wort, kava, garlic, ginger, gingko&#xD;
             biloba, or guarana within 14 days prior to admission&#xD;
&#xD;
          -  Consumption of grapefruit or grapefruit-containing foods or juices within 7 days prior&#xD;
             to dosing or any time during the study&#xD;
&#xD;
          -  Heavy caffeine drinkers defined by a regular intake of more than 5 cups (40-50 mg of&#xD;
             caffeine per cup) of coffee (or equivalent in xanthine-containing beverages) per day&#xD;
             or caffeine drinking subjects who have not had consistent daily caffeine consumption&#xD;
             for 1 month prior to study entry or subjects not willing to maintain consistent&#xD;
             caffeine consumption during the study&#xD;
&#xD;
          -  Have participated in a [14C]-study within the last 12 months. The previous&#xD;
             radiolabeled study drug must have been received more than 6 months prior to Check-in&#xD;
             for this study and the cumulative annual radiation exposure must be consistent with&#xD;
             Food and Drug Administration (FDA) recommendations, for example whole body exposure&#xD;
             less than 5,000 mrem/year&#xD;
&#xD;
          -  Exposure to significant radiation within 12 months prior to dose (for example, serial&#xD;
             X-ray or computed tomography scans, barium meal, current employment in a job requiring&#xD;
             radiation exposure monitoring)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY(1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <study_first_submitted>January 10, 2011</study_first_submitted>
  <study_first_submitted_qc>January 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2011</study_first_posted>
  <last_update_submitted>April 14, 2011</last_update_submitted>
  <last_update_submitted_qc>April 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2011</last_update_posted>
  <responsible_party>
    <name_title>Chief Medical Officer</name_title>
    <organization>Eli Lilly</organization>
  </responsible_party>
  <keyword>Absorption</keyword>
  <keyword>Distribution</keyword>
  <keyword>Metabolism</keyword>
  <keyword>Excretion</keyword>
  <keyword>Mass balance</keyword>
  <keyword>Metabolic profile</keyword>
  <keyword>Radiolabeled study</keyword>
  <keyword>14C</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

